|
|
Volumn 145, Issue 2, 2001, Pages 350-351
|
|
Efficacy of basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in a patient with severe chronic atopic dermatitis [2]
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
CHIMERIC ANTIBODY;
CORTICOSTEROID;
CYCLOSPORIN;
CYCLOSPORIN A;
IMMUNOGLOBULIN E;
INTERLEUKIN 2;
INTERLEUKIN 2 RECEPTOR;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
MONOCLONAL ANTIBODY;
STEROID;
VALACICLOVIR;
ADULT;
ATOPIC DERMATITIS;
CASE REPORT;
CHRONIC DISEASE;
CLINICAL FEATURE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DOSE TIME EFFECT RELATION;
DRUG EFFICACY;
DRUG RECEPTOR BINDING;
ECZEMA;
FEMALE;
HERPES VIRUS INFECTION;
HUMAN;
IMMUNOPROPHYLAXIS;
IMMUNOSUPPRESSIVE TREATMENT;
LETTER;
LYMPHOCYTE PROLIFERATION;
PRIORITY JOURNAL;
PRURITUS;
PSORIASIS;
PYELONEPHRITIS;
RANDOMIZED CONTROLLED TRIAL;
RECEPTOR AFFINITY;
SLEEP DEPRIVATION;
T LYMPHOCYTE ACTIVATION;
TREATMENT FAILURE;
TREATMENT OUTCOME;
URINARY TRACT INFECTION;
ADULT;
ANTIBODIES, MONOCLONAL;
CHRONIC DISEASE;
DERMATITIS, ATOPIC;
FEMALE;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
RECOMBINANT FUSION PROTEINS;
TREATMENT OUTCOME;
|
|
EID: 0034799416
PISSN: 00070963
EISSN: None
Source Type: Journal
DOI: 10.1046/j.1365-2133.2001.04353.x Document Type: Letter |
|
Times cited : (18)
|
|
References (8)
|
